Purpose
To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.
Patients and Methods
Patients with HER2-positive advanced gastroesophageal adenocarcinoma were randomly assigned at a one-to-one ratio to CapeOx plus lapatinib 1,250 mg or placebo daily. Primary end point was overall survival (OS) in patients with centrally confirmed HER2 amplification in the primary efficacy population.
Results
A total of 545 patients were randomly assigned, and 487 patients comprised the primary efficacy population. Median OS in the lapatinib and placebo arms was 12.2 (95% CI, 10.6 to 14.2) and 10.5 months (95% CI, 9.0 to 11.3), respectively, which was not significantly different (hazard ratio, 0.91; 95% CI, 0.73 to 1.12). Median progression-free survival in the lapatinib and placebo arms was 6.0 (95% CI, 5.6 to 7.0) and 5.4 months (95% CI, 4.4 to 5.7) , respectively (hazard ratio, 0.82; 95% CI, 0.68 to 1.00; P = .0381). Response rate was significantly higher in the lapatinib arm: 53% (95% CI, 46.4 to 58.8) compared with 39% (95% CI, 32.9 to 45.3) in the placebo arm (P = .0031). Preplanned exploratory subgroup analyses showed OS in the lapatinib arm was prolonged in Asian and younger patients. No correlation was observed between HER2 immunohistochemistry status and survival. There were increased toxicities in the lapatinib arm, particularly diarrhea.
INTRODUCTION
Gastric cancer is the third most common cause of cancer-related death worldwide. 1 There is no standard first-line chemotherapy for this disease, but current treatment options include a combination of a fluoropyrimidine and platin, such as cisplatin or oxaliplatin. 2 Despite advances in cytotoxic therapies, survival for patients with metastatic disease remains poor, with few patients remaining alive 2 years after initiation of treatment. [3] [4] [5] Human epidermal growth factor receptor 2 (HER2) is associated with approximately 20% of gastroesophageal adenocarcinomas, 6, 7 and targeted inhibition of HER2 has been shown to significantly improve outcomes in patients with breast cancer overexpressing or amplifying HER2. 8, 9 Lapatinib is a small-molecule tyrosine kinase inhibitor of epidermal growth factor receptor and HER2, approved for the treatment of HER2-positive breast cancer. 10 In vitro and in vivo studies with lapatinib in HER2-amplified upper GI cell lines have demonstrated significant antitumor effects.
11
A 9% response rate was seen with lapatinib monotherapy in patients with gastroesophageal adenocarcinoma.
12 At the outset of this study, no anti-HER2 agent had demonstrated improved survival in this disease. Therefore, the TRIO-013 (Translational Research in Oncology)/LOGiC (Lapatinib Optimization Study in the HER2-Positive Gastric Cancer) trial was conducted to assess the clinical benefit and safety of adding lapatinib to capecitabine and oxaliplatin (CapeOx) as first-line chemotherapy.
PATIENTS AND METHODS

Study Design and Treatment
TRIO-013/LOGiC was a multicenter, double-blind, randomized phase III study conducted at 186 centers in 22 countries in Asia, Europe, North America, and South America. The study was conducted in accordance with the current ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.
13,14 Written informed consent was obtained from each patient before the performance of any study-specific procedures. When deviations from GCP were detected, corrective and preventative actions were implemented, and the appropriate regulatory authorities and ethics committees were notified.
Patients were randomly assigned at a one-to-one ratio to CapeOx (capecitabine 1,700 mg/m 2 and oxaliplatin 130 mg/m 2 ) plus lapatinib 1,250 mg (lapatinib arm) or to CapeOx plus placebo (placebo arm). Treatment was administered in 21-day cycles, consisting of intravenous oxaliplatin on day 1 (for up to eight cycles) and oral capecitabine in two daily doses (morning and evening) from day 1 to 14. Oral lapatinib or placebo were administered continuously and treated until progressive disease, unacceptable toxicity, or withdrawal; safety and disease assessments were performed throughout the study. If any study drugs were stopped, patients could continue receiving the remaining drugs. Random assignment was performed centrally and stratified by prior adjuvant and/or neoadjuvant chemotherapy (yes v no) and by geographic region (North America, Asia, or rest of world [ROW] ).
Patients
Eligible patients were age $ 18 years and had histologically confirmed unresectable adenocarcinoma of the stomach, esophagus, or gastroesophageal junction with radiologically evaluable disease according to RECIST, 15 Eastern Cooperative Oncology Group performance status # 2, and adequate organ function. No prior palliative chemotherapy was allowed, and prior treatment with oxaliplatin-based neoadjuvant or adjuvant chemotherapy could not have been completed , 12 months before study entry. Tumors had to have HER2 amplification by fluorescence in situ hybridization (FISH) assessed by local or designated central laboratory. If unavailable, immunohistochemistry (IHC; 3+) or HER2 amplification by chromogenic or silver in situ hybridization was permitted. The Appendix (online only) provides full inclusion and exclusion criteria.
End Points and Assessments
The primary end point was overall survival (OS), defined as the time from random assignment until death resulting from any cause. Previous analyses of studies with lapatinib in patients with breast cancer showed benefit only in patients with HER2 amplification, regardless of IHC status.
16 Therefore, efficacy analyses were performed in the primary efficacy population (PEP), consisting of patients with disease confirmed for HER2 amplification as determined by FISH in the central laboratories (Appendix).
Secondary end points included progression-free survival (PFS), defined as the time from random assignment until the earliest date of disease progression or death resulting from any cause; best overall response rate, defined as the percentage of patients experiencing a confirmed complete response or partial response; duration of response (DoR); quality of life (QoL); and safety assessments (including drug exposure). Early deaths (ie, death , 30 days after first dose of study drug) were assessed in the safety population as post hoc analyses. Preplanned exploratory efficacy analyses included subgroup analysis of OS based on geographic region (Asia, North America, or ROW), prior adjuvant use, age, baseline Eastern Cooperative Oncology Group status, primary disease site, histologic cancer type, whether pylorus was intact, and HER2 FISH or IHC status. Treatment responses were evaluated by the investigator using RECIST (version 1.0). 15 Severity of adverse events (AEs) was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0).
17 Change in health-related QoL was also assessed using patient questionnaires. An independent data safety monitoring committee regularly reviewed study data for safety and efficacy.
Sample Size and Statistical Analysis
Initially, the planned sample size was 410 patients, with PFS as the primary end point. After the ToGA (Trastuzumab for Gastric Cancer) trial results were released, the primary end point was changed to OS, and the study was powered to test the hypothesis that addition of lapatinib to CapeOx would improve median OS from 11.1 to 13.1 months (hazard ratio [HR], 0.74).
18 To ensure 80% power for a two-sided log-rank test at an a of 0.05, 337 events were necessary. On the basis of these assumptions, 454 patients were required in the PEP. Assuming discordance between local and central FISH testing of approximately 15%, a sample size of 535 patients was planned.
OS and PFS were compared between the two treatment arms using a two-sided stratified log-rank test, stratifying for prior adjuvant or neoadjuvant chemotherapy and region. Kaplan-Meier estimates were calculated for median OS, PFS, and DoR (Appendix). A sensitivity analysis was performed for PFS, with censoring of the patients who were switched to nonprotocol therapies before disease progression. Additional sensitivity analyses to assess OS, PFS, and safety were conducted after significant deviations from GCP at three study sites in Poland; these analyses excluded a total of 27 patients (lapatinib arm, n = 13; placebo arm, n = 14) from the PEP.
RESULTS
Patients
A total of 545 patients were randomly assigned between June 2008 and January 2012 and comprised the intent-to-treat (ITT) population. The PEP included all randomly assigned patients with centrally confirmed HER2-positive status (lapatinib arm, n = 249; placebo arm, n = 238). There were 537 patients in the safety population (lapatinib arm, n = 270; placebo arm, n = 267). Patient flow is summarized in Figure 1 .
Patient demographic and baseline characteristics in the PEP were similar between treatment arms (Table 1 ). In the lapatinib and placebo arms, respectively, 7% and 8% of patients had received prior adjuvant or neoadjuvant treatment, 40% and 39% patients were from Asia (majority from China or South Korea), and 57% (both treatment arms) were from the ROW (excluding North America). There were no major differences in baseline characteristics between the PEP and ITT population (data not shown).
Overall, 5% and 8% patients received trastuzumab as followup therapy (Asia, 9% and 12%; ROW, 1% and 4%) in the lapatinib and placebo arms, respectively. A majority of Asian patients receiving post-study trastuzumab were South Korean.
Efficacy
The cutoff date for primary efficacy analysis was September 24, 2012, after 350 deaths had occurred. Median follow-up was 23 months. The primary end point (ie, median OS in PEP) was 12.2 months (95% CI, 10.6 to 14.2) in the lapatinib arm and 10.5 months (95% CI, 9.0 to 11.3) in the placebo arm (Fig 2A) , which was not statistically significant (HR, 0.91; 95% CI, 0.73 to 1.12; P = .3492). ITT analysis of OS was consistent with the results in the PEP, with an HR of 0.91 (95% CI, 0.74 to 1.10; P = .3244). Similar OS values were observed in the sensitivity analyses after excluding 27 patients from three sites with significant protocol deviations (HR, 0.90; 95% CI, 0.73 to 1.12; P = .3252). Because the trial missed its primary end point of OS, all other analyses are reported with a descriptive intent.
A significant difference between the lapatinib and placebo arms was observed for PFS in the PEP (HR, 0.82; 95% CI, 0.68 to 1.00; P = .0381). Median PFS values were 6.0 months (95% CI, 5.6 to 7.0) in the lapatinib arm and 5.4 months (95% CI, 4.4 to 5.7) in the placebo arm (Fig 2B) . Similar PFS values were observed in the sensitivity analyses (HR, 0.82; 95% CI, 0.67 to 1.00; P = .0381). In the sensitivity analysis with censoring at the time a patient received nonprotocol therapy, median PFS values in the lapatinib and placebo arms were 6.0 (95% CI, 5.6 to 6.9) and 5.3 months (95% CI, 4.4 to 5.7), respectively; Cumulative Survival (probability) observed between the lapatinib and placebo arms in healthrelated QoL (Appendix).
Preplanned exploratory analyses included OS by geographic region and age. In the Asian subgroup, median OS was 16.5 months (95% CI, 13.3 to 20.2) in the lapatinib arm and 10.9 months (95% CI, 9.0 to 14.9) in the placebo arm (HR, 0.68; 95% CI, 0.48 to 0.96; P = .0261; Figs 3 and 4) . In the ROW subgroup, however, median OS was 10.0 months (95% CI, 8.0 to 12.0) in the lapatinib arm and 9.1 months (95% CI, 8.3 to 10.9) in the placebo arm (HR, 1.04; 95% CI, 0.79 to 1.37; P = .7781; Figs 3 and 4A). In patients age , 60 years, median OS was 12.9 months (95% CI, 11.1 to 16.0) in the lapatinib arm and 9.0 months (95% CI, 7.8 to 11.3) in the placebo arm (HR, 0.69; 95% CI, 0.51 to 0.94; P = .0141; Figs 3 and 4B) . In patients age $ 60 years, median OS was 11.3 months (95% CI, 8.4 to 13.8) in the lapatinib arm and 10.9 months (95% CI, 9.6 to 14.1) in the placebo arm (HR, 1.08; 95% CI, 0.81 to 1.45; P = .5923; Figs 3 and 4B) .
Post hoc analysis of the OS data by region and age showed that patients age , and $ 60 years from Asia had HRs of 0.60 (95% CI, 0.38 to 0.94) and 0.80 (95% CI, 0.47 to 1.36), respectively. Outside of Asia, patients age , 60 years had an HR of 0.74 (95% CI, 0.49 to 1.11), whereas those age $ 60 years had an HR of 1.32 (95% CI, 0.91 to 1.90; Fig 5 [ Multivariable Cox regression analysis of PFS and OS revealed statistically significant effects of region (favoring Asian patients), age (favoring younger patients), pylorus status (favoring pylorus intact), histology (favoring nondiffuse histology), and treatment (favoring lapatinib), as well as an interaction between age and treatment (larger effect of lapatinib in younger patients [Data Supplement] ). In these multivariable analyses, the effect of lapatinib treatment on PFS had an HR of 0.176 (95% CI, 0.062 to 0.495; P = .0010) and on OS had an HR of 0.304 (95% CI, 0.099 to 0.936; P = .0379).
No correlation was observed between IHC status and OS benefit from lapatinib in this FISH-positive population. OS HR for IHC 0 to 1+ was 0.91 (95% CI, 0.55 to 1.51; P = .7082) and for IHC 2 to 3+ was 0.86 (95% CI, 0.68 to 1.09; P = .2105; Fig 3) .
Safety
In the lapatinib arm, 255 patients (94%) experienced AEs, and 72 patients (27%) experienced serious AEs, compared with 236 (88%)
Cumulative Survival (probability) Cumulative Survival (probability) 
Median (95% CI; mo) 12.9 (11.1 to 16.0) 9.0 (7.8 to 11.3) HR (95% CI) 0.69 (0.51 to 0.94)
10.0 (8.0 to 12.0) 9.1 (8.3 to 10.9) HR (95% CI)
1.04 (0.79 to 1.37) www.jco.org and 52 patients (19%) experiencing AEs and serious AEs, respectively, in the placebo arm (Table 2) . Fifty-seven patients (21%) experienced an AE leading to study drug discontinuation in the lapatinib arm, compared with 50 (19%) in the placebo arm (Table 2) . Overall incidence of AEs observed in the sensitivity analyses was similar.
The most common AEs in both arms were diarrhea, nausea, vomiting, and decreased appetite ( Table 2) . A majority of these AEs were grade 1 to 2 in severity. More patients experienced grade 1 to 2 and grade $ 3 AEs in the lapatinib arm. Diarrhea, in particular, was increased, with overall diarrhea experienced in 58% of patients in the lapatinib arm, compared with 29% of patients in the placebo arm. Grade $ 3 diarrhea was experienced by 12% of patients in the lapatinib arm and 3% in the placebo arm (Table 2) .
Fifteen patients (6%) experienced fatal serious AEs in the lapatinib arm (Table 2) , four of which were attributed to study treatment, whereas nine (3%) experienced serious AEs in the placebo arm, one of which was attributed to study treatment (Appendix). Post hoc analysis seemed to show numeric differences in early deaths (, 30 days) between the lapatinib and placebo arms in patients in the ROW (12% v 5%), particularly in patients age $ 60 years (7% v 1% [Data Supplement]). Relative drug exposure was slightly lower in the lapatinib arm but was similar overall between treatments (Data Supplement).
DISCUSSION
Both lapatinib-and trastuzumab-based regimens improve outcomes in patients with HER2-positive breast cancer. Preclinical and early clinical studies also showed lapatinib to have activity in upper GI cancers with HER2 amplification.
11 Although the addition of the anti-HER2 antibody trastuzumab to cisplatin-based therapy in the ToGA trial resulted in a significant improvement in OS, 18 adding lapatinib to CapeOx in the first-line treatment of patients with advanced gastroesophageal adenocarcinoma in our study did not significantly improve OS, and a higher incidence of AEs was observed in the lapatinib arm. However, lapatinib treatment was not without effect, and preplanned subgroup and additional post hoc multivariable analyses revealed striking differences in outcomes in some populations, especially patients from Asia and younger patients (age , 60 years).
(n = 53) (n = 54) Median (95% CI; mo) 15.7 (11.9 to 19.4) 10.5 (7.8 to 12.6 Cumulative Survival (probability) There are several possible explanations for these results. Trastuzumab may have superior efficacy against HER2-positive cancers compared with lapatinib. Although the addition of lapatinib to capecitabine in patients with HER2-positive breast cancer, for whom trastuzumab-containing therapy had failed, was shown to improve survival, 9 a recent breast cancer study showed lapatinib to be inferior to trastuzumab in combination with chemotherapy in the metastatic setting.
19 There also may be biologic differences between HER2-positive breast and gastroesophageal cancers. Even with trastuzumab treatment, patients with HER2-positive gastric cancer have a relatively short survival, with few patients living . 3 years.
18
Lapatinib and trastuzumab have distinct toxicity profiles, and the addition of lapatinib to chemotherapy in the TRIO-013/LOGiC trial increased some specific toxicities, particularly diarrhea, which was not experienced frequently with the addition of trastuzumab. Patients with gastroesophageal cancer may be less able to tolerate GI toxicities than patients with breast cancer, leading to decreased efficacy or reduced patient compliance.
Despite the advantages of patient convenience with oral agents, concerns exist about absorption of such agents. Feeding alone has been shown to significantly change lapatinib absorption. 20 Twenty-three percent of patients had their pylorus removed in this study, which could have affected emptying, and in this subgroup, there was no benefit in terms of OS (HR, 1.06; 95% CI, 0.67 to 1.68), as opposed to patients with an intact pylorus (HR, 0.80; 95% CI, 0.63 to 1.01). No pharmacokinetics were performed in this trial, but in the recently published second-line phase III TyTan (Tykerb With Taxol in Asian HER2-Positive Gastric Cancer) trial of paclitaxel with or without lapatinib, in a small subset of patients, those with an intact pylorus had higher plasma levels of lapatinib.
21
There was also significant variability of effect of lapatinib and patient location. In the 40% of patients from Asia, a clear benefit was observed in OS with the addition of lapatinib (HR, 0.68; 95% CI, 0.48 to 0.96), which was not seen in other patients (Fig 3) . This difference between Asian and non-Asian patients was not observed in the ToGA trial, in which Asian patients had an HR of 0.82 (95% CI, 0.61 to 1.11), which was similar to the overall improvement (HR, 0.74; 95% CI, 0.60 to 0.91) and less than the improvement seen in Latin American and European patients. 18 The TyTan trial, conducted only in Asian patients, showed a trend toward improved survival with the addition of lapatinib (especially in non-Japanese Asians) but did not reach statistical significance. 21 Other trials with biologic agents, such as the AVAGAST (Avastin in Gastric Cancer) trial with bevacizumab, have also found differences between Asian and non-Asian patients, although in these cases, Asian patients did not benefit from the targeted therapy. 4 Gastric cancers in Asian populations differ from those in the West and, in some populations (including Chinese and Japanese patients), are more likely to occur in younger patients, be more distal, and have intestinal histology. 22 There may be additional molecular differences, with recent studies showing lack of correlation between Lauren histologic classification and genetic alterations and the presence of multiple molecular subtypes. 23 Other potential differences between Asian and non-Asian patients may include body mass, more frequent use of second-or third-line therapy, surgery type, toxicity tolerance, and physicians' experience with patients with gastric cancer.
Another observation was the difference in the effect of lapatinib between older and younger patients. In lapatinibtreated patients age , 60 years, there was a significant improvement in OS (HR, 0.69; 95% CI, 0.51 to 0.94), which was not seen in older patients (HR, 1.08; 95% CI, 0.81 to 1.45). In a post hoc subgroup analysis, both younger and older Asian patients benefited, whereas there was a major difference in outcome between older and younger non-Asian patients. Possible explanations for this include differing biology between older and younger patients and tolerance of toxicities. However, a different effect on OS with age was observed in the ToGA trial (age , 60 years: HR, 0.84; 95% CI, 0.62 to 1.14; age $ 60 years: HR, 0.66; 95% CI, 0.49 to 0.88), 18 with older www.jco.org patients (age . 60 years) experiencing an improved OS compared with younger patients after treatment with lapatinib. The use of lapatinib in combination with CapeOx in patients with HER2-positive gastric cancer cannot be recommended. Future research may identify a subgroup of patients who benefit from such treatment, although there are several new anti-HER2 agents, such as pertuzumab and ado-trastuzumab, that are being tested in HER2-positive gastric cancer. Recently published Cancer Genome Atlas data revealed additional molecular subgroups in a population of Western and Asian gastric cancers. 24 In breast cancer, lapatinib in combination with trastuzumab has activity superior to that of either single agent, which was also seen in preclinical gastric cancer models and may be worth examining in the future.
